Trials / Completed
CompletedNCT00456053
A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 145 (actual)
- Sponsor
- Kyntra Bio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test the safety and efficacy of FG-2216 in the treatment of patients with renal anemia who are not receiving erythropoietin and who are not on dialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FG2216 |
Timeline
- Start date
- 2005-12-01
- Completion
- 2007-07-01
- First posted
- 2007-04-04
- Last updated
- 2007-11-06
Locations
27 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00456053. Inclusion in this directory is not an endorsement.